Martina Damo

Cette personne n’est plus à l’EPFL

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (5)

Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes

Jeffrey Alan Hubbell, Sachiko Hirosue, Xavier Fredy René Quaglia-Thermes, Martina Damo, David Scott Wilson, Giacomo Olimpio Diaceri, Michal Mateusz Raczy

Homeostatic antigen presentation by hepatic antigen-presenting cells, which results in tolerogenic T-cell education, could be exploited to induce antigen-specific immunological tolerance. Here we show that antigens modified with polymeric forms of either N ...

2019

Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity

Jeffrey Alan Hubbell, Melody Swartz, Lambert Charles François Potin, Martina Damo, Jun Ishihara, Kazuto Fukunaga

CD40 is an immune costimulatory receptor expressed by antigen-presenting cells. Agonistic anti-CD40 antibodies have demonstrated considerable antitumor effects yet can also elicit serious treatment-related adverse events, such as liver toxicity, including ...

AMER ASSOC CANCER RESEARCH2018

Hepatocyte-dependent cross-presentation of soluble antigens induces antigen-specific CD8(+) T cell tolerance

Jeffrey Alan Hubbell, Martina Damo, David Scott Wilson

Amer Assoc Immunologists2016

Bioengineering approaches in immunotherapy : from basic to translational applications

Martina Damo

Vaccination has been regarded to as the most attractive immunotherapy for cancer because of its ability to instruct immune cells to recognize and kill tumor cells. Exosomes are one of the most recent discoveries translated from basic biology into experimen ...

EPFL2016

TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma

Jeffrey Alan Hubbell, Eleonora Simeoni, Martina Damo, David Scott Wilson

Dendritic cell (DC)-derived exosomes (Dexo) contain the machinery necessary to activate potent antigen-specific immune responses. As promising cell-free immunogens, Dexo have been tested in previous clinical trials for cancer vaccine immunotherapy, yet res ...

Nature Publishing Group2015

Page 1 sur 1